Moleculin Biotech ( (MBRX) ) just unveiled an update.
Moleculin Biotech, a pharmaceutical company focused on treating challenging tumors and viruses, is set to release its third-quarter financial results on November 8, 2024. The company will host a conference call and webcast on November 11, 2024, to discuss these results. Moleculin is advancing several promising drugs, including Annamycin for leukemia, and WP1066 targeting cancers and viruses, positioning itself for potential breakthroughs in these areas.
For detailed information about MBRX stock, go to TipRanks’ Stock Analysis page.
